Liso-Cel therapy administered in the Outpatient community setting in patients with R/R Large B-Cell Lymphoma

In the first and largest study (A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/​R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting - TRANSCEND-OUTREACH-007) to prospectively assess chimeric antigen receptor (CAR) T-cell therapy with outpatient monitoring in community medical centers, lisocabtagene maraleucel (liso-cel) administered at these sites demonstrated meaningful efficacy with a positive safety profile in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), according to results published in Blood Advances.

Key Takeaways

• The OUTREACH trial assessed liso-cel CAR-T therapy in community centers, showing comparable safety and efficacy in outpatient and inpatient settings.
• The study reported an overall response rate of 80% for liso-cel, with similar outcomes in both outpatient and inpatient settings.
• CAR T-cell therapy on an outpatient basis could lead to greater adherence and less financial and physical burdens.

source